NVIDIA CorporationNVIDIA AI computing system deployed by Bristol Myers Squibb, highlighting demand for its AI hardware.
Arm Holdings CEO Rene Haas said artificial intelligence could help find a cure for cancer within our lifetime, but warned that chip shortages are limiting the expansion of AI infrastructure. In an interview with the BBC, Haas said AI could eventually solve complex problems in cancer research and accelerate drug development, though modelling cells and DNA markers remains too complex today. The computing requirements for AI-driven drug discovery are already substantial, with Generate Biomedicines co-founder Gevorg Grigoryan noting that large-scale model training needs access to many GPUs, plus proprietary biological data. Bristol Myers Squibb has deployed a new NVIDIA AI computing system to support research across cancer and other therapeutic areas. Haas described the industry as in an "absolutely supply-constrained environment," saying more chip factories are needed to support growing data centers, but manufacturing capacity cannot be added overnight. He also said Arm's power-efficient technology is used in about half of AI data centers worldwide, and demand for Arm's AGI chip, developed with Meta Platforms, has exceeded $2 billion since its launch.
NVIDIA CorporationNVIDIA AI computing system deployed by Bristol Myers Squibb, highlighting demand for its AI hardware.
Meta Platforms Inc.Demand for Arm's AGI chip developed with Meta exceeds $2 billion, indicating strong product adoption.
Arm Holdings plc American Depositary Shares
Bristol-Myers Squibb CompanyBristol Myers Squibb deployed NVIDIA AI system for cancer research, benefiting from AI advancements.
Generate Biomedicines, Inc. Common Stock
BBC Co. Ltd.
CTO Realty Growth Inc